-
New Drug Safety Panel Will Mean More FDA Scrutiny of Drugs Already on Market, But Perhaps Not Enough
Congress Should Give FDA Authority to Impose New Labeling Language on Approved Drugs Without Needing Big Pharma’s Permission When Health and Human Services (HHS) Secretary Michael Leavitt was announcing the new Drug Safety Oversight…
-
Upcoming Vioxx Trials: The Fall 2005 Line-up for Merck and Its Lawyers
A Summary of the Vioxx Lawsuits Coming Soon in New Jersey, Texas, and Louisiana As is well-known by now, Merck & Co. lost its first Vioxx trial in a Texas state court last week,…
-
Patients Discharged From Hospital Often Lack Sufficient Knowledge About Their Medications
Drug-safety Issue: Prescription Medication Noncompliance Due to Patient Misunderstanding In the August 2005 issue of Mayo Clinic Proceedings (Mayo Clin Proc 2005;80:991-994) a small study report suggests that poor communication with patients when being…
-
Ernst v. Merck Vioxx Trial: Massive Verdict for Plaintiff; Knock-out Punch for Merck?
Merck Vows to Fight All Comers Despite Texas Jury’s Condemnation of Vioxx to Tune of $253 Million On August 19, 2005 Merck & Co. was found negligent in the nation’s first Vioxx trial, Carol…
-
Abbott’s Weight-loss Drug Meridia Gets a Confidence Vote by FDA
FDA Denies Public Citizen’s Petition to Remove Meridia from Market The FDA has decided that the benefits of Abbott Laboratories’ prescription weight-loss drug Meridia continue to outweigh the drug’s risks for select obese…
-
Crawford & Co. Go on Tour: FDA Road Show Will Visit Miami, Boston, and Phoenix
"Vision 2006" Public Meetings to be Hosted by FDA Commissioner Lester Crawford According to news reports published August 16, 2005, Lester Crawford, the new head of the FDA, will be putting on a series…
